First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
07 déc. 2022 07h30 HE
|
Vor Biopharma
Trem-cel (formerly VOR33) successfully manufactured and engrafted normallyBlood counts successfully maintained following post-transplant treatment with MylotargConference call scheduled for today,...
Vor Bio to Participate in Upcoming Investor Conferences
22 nov. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
10 nov. 2022 16h15 HE
|
Vor Biopharma
Initial clinical data for VOR33 on track for Q4 2022Eyal C. Attar, M.D. appointed as Chief Medical OfficerInitiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass.,...
Vor Bio to Participate in Upcoming Investor Conferences
01 nov. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
12 oct. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief...
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
11 oct. 2022 08h00 HE
|
Vor Biopharma
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European...
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
28 sept. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the opening of its new in-house clinical...
Vor Bio to Participate in Upcoming Investor Conferences
06 sept. 2022 16h15 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
11 août 2022 16h15 HE
|
Vor Biopharma
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at...
Vor Bio to Participate in Upcoming Investor Conferences
01 août 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...